Protagonist Therapeutics (PTGX) Net Cash Flow (2015 - 2026)

Protagonist Therapeutics has disclosed Net Cash Flow across 12 years of filings, most recently posting $65.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $65.3 million, up 54.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $54.1 million (up 264.43% YoY), and the FY2025 annual result was $31.2 million, up 134.87% from the prior year.
• Net Cash Flow came in at $65.3 million for Q1 2026 at Protagonist Therapeutics, up from $14.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $183.1 million in Q2 2024 to a low of -$224.5 million in Q3 2024.
• The 5-year median for Net Cash Flow is $1.9 million (2023), against an average of $4.1 million.
• Across the five-year window, Net Cash Flow plunged 4524.55% in 2024 and jumped 399.48% in 2025, its largest moves.
• Protagonist Therapeutics' Net Cash Flow stood at -$27.1 million in 2022, then slumped by 61.34% to -$43.8 million in 2023, then rose by 22.67% to -$33.9 million in 2024, then jumped by 143.33% to $14.7 million in 2025, then soared by 345.07% to $65.3 million in 2026.
• The last three Net Cash Flow figures came in at $65.3 million (Q1 2026), $14.7 million (Q4 2025), and -$54.8 million (Q3 2025), per Business Quant data.